Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways.
Fuente:
PubMed
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artículo científico |
| Lenguaje: | en |
| Publicado: |
Marine drugs
2025
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1868266252622888961 |
|---|---|
| author | Huang, Jing Li, Lei Xu, Liyan Feng, Lixin Wang, Yuxin Sik, Attila Gabor Jin, Meng Wang, Rongchun Liu, Kechun Li, Xiaobin |
| author_facet | Huang, Jing Li, Lei Xu, Liyan Feng, Lixin Wang, Yuxin Sik, Attila Gabor Jin, Meng Wang, Rongchun Liu, Kechun Li, Xiaobin Huang, Jing Li, Lei Xu, Liyan Feng, Lixin Wang, Yuxin Sik, Attila Gabor Jin, Meng Wang, Rongchun Liu, Kechun Li, Xiaobin |
| collection | PubMed - marine biology |
| contents | Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Huang, Jing Li, Lei Xu, Liyan Feng, Lixin Wang, Yuxin Sik, Attila Gabor Jin, Meng Wang, Rongchun Liu, Kechun Li, Xiaobin Animals Zebrafish NF-kappa B Inflammatory Bowel Diseases Signal Transduction Anti-Inflammatory Agents Disease Models, Animal Toll-Like Receptors Hydroxybenzoates Molecular Docking Simulation Trinitrobenzenesulfonic Acid Aquatic Organisms Inflammatory bowel disease (IBD) is characterized by uncontrolled, chronic relapsing inflammation in the gastrointestinal tract and has become a global healthcare problem. Here, we aimed to illustrate the anti-inflammatory activity and the underlying mechanism of methyl 3-bromo-4,5-dihydroxybenzoate (MBD), a compound derived from marine organisms, especially in IBD, using a zebrafish model. The results indicated that MBD could inhibit the inflammatory responses induced by CuSO, tail amputation and LPS in zebrafish. Furthermore, MBD notably inhibited the intestinal migration of immune cells, enhanced the integrity of the gut mucosal barrier and improved intestinal peristalsis function in a zebrafish IBD model induced by trinitro-benzene-sulfonic acid (TNBS). In addition, MBD could inhibit ROS elevation induced by TNBS. Network pharmacology analysis, molecular docking, transcriptomics sequencing and RT-PCR were conducted to investigate the potential mechanism. The results showed that MBD could regulate the TLR/NF-κB pathways by inhibiting the mRNA expression of , , , , , , , , , , , , , , and , and promoting the mRNA expression of , and In conclusion, these findings indicate that MBD could be a potential candidate for the treatment of IBD. |
| format | Artículo científico |
| id | pubmed_39852549 |
| institution | PubMed |
| language | en |
| publishDate | 2025 |
| publisher | Marine drugs |
| record_format | pubmed |
| spellingShingle | Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Huang, Jing Li, Lei Xu, Liyan Feng, Lixin Wang, Yuxin Sik, Attila Gabor Jin, Meng Wang, Rongchun Liu, Kechun Li, Xiaobin Animals Zebrafish NF-kappa B Inflammatory Bowel Diseases Signal Transduction Anti-Inflammatory Agents Disease Models, Animal Toll-Like Receptors Hydroxybenzoates Molecular Docking Simulation Trinitrobenzenesulfonic Acid Aquatic Organisms Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. Huang, Jing Li, Lei Xu, Liyan Feng, Lixin Wang, Yuxin Sik, Attila Gabor Jin, Meng Wang, Rongchun Liu, Kechun Li, Xiaobin Animals Zebrafish NF-kappa B Inflammatory Bowel Diseases Signal Transduction Anti-Inflammatory Agents Disease Models, Animal Toll-Like Receptors Hydroxybenzoates Molecular Docking Simulation Trinitrobenzenesulfonic Acid Aquatic Organisms Inflammatory bowel disease (IBD) is characterized by uncontrolled, chronic relapsing inflammation in the gastrointestinal tract and has become a global healthcare problem. Here, we aimed to illustrate the anti-inflammatory activity and the underlying mechanism of methyl 3-bromo-4,5-dihydroxybenzoate (MBD), a compound derived from marine organisms, especially in IBD, using a zebrafish model. The results indicated that MBD could inhibit the inflammatory responses induced by CuSO, tail amputation and LPS in zebrafish. Furthermore, MBD notably inhibited the intestinal migration of immune cells, enhanced the integrity of the gut mucosal barrier and improved intestinal peristalsis function in a zebrafish IBD model induced by trinitro-benzene-sulfonic acid (TNBS). In addition, MBD could inhibit ROS elevation induced by TNBS. Network pharmacology analysis, molecular docking, transcriptomics sequencing and RT-PCR were conducted to investigate the potential mechanism. The results showed that MBD could regulate the TLR/NF-κB pathways by inhibiting the mRNA expression of , , , , , , , , , , , , , , and , and promoting the mRNA expression of , and In conclusion, these findings indicate that MBD could be a potential candidate for the treatment of IBD. |
| title | Methyl 3-Bromo-4,5-dihydroxybenzoate Attenuates Inflammatory Bowel Disease by Regulating TLR/NF-κB Pathways. |
| topic | Animals Zebrafish NF-kappa B Inflammatory Bowel Diseases Signal Transduction Anti-Inflammatory Agents Disease Models, Animal Toll-Like Receptors Hydroxybenzoates Molecular Docking Simulation Trinitrobenzenesulfonic Acid Aquatic Organisms |
| url | https://pubmed.ncbi.nlm.nih.gov/39852549/ |